NCT02555813 - Treatment of Pancreatic Cancer With Abraxane | Biotech Hunter

Enrollment

317

Participants

Timeline

Start Date

May 8, 2015

Primary Completion Date

September 7, 2020

Study Completion Date

September 7, 2020

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Abraxane

Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity

DRUG

Gemcitabine

Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity

Trial Locations (19)

1130

KH St. Josephs, Vienna

1140

KH Hanusch, Vienna

3500

KH Krems, Krems

6511

KH Zams, Zams

7001

BHB Eisenstadt, Eisenstadt

8010

Medical University Graz, Graz

9020

KH Elisabethinen Klagenfurt, Klagenfurt

LKH Klagenfurt, Klagenfurt

6800:

LKH Feldkirch, Feldkirch

6020:

Medical University Innsbruck, Innsbruck

8700:

LKH Leoben, Leoben

4020:

KH Barmherzige Schwestern Linz, Linz

5020:

LKH Salzburg, Salzburg

3100:

LKH St. Pölten, Sankt Pölten

4400:

LKH Steyr, Steyr

1090:

Medical University Vienna, Vienna

4840:

LKH Vöcklabruck, Vöcklabruck

4600:

Klinikum Wels, Wels

2700:

LKH Wr. Neustadt, Wiener Neustadt